AMPHIVENA THERAPEUTICS
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.
AMPHIVENA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2012-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.amphivena.com
Total Employee:
11+
Status:
Active
Contact:
415-994-6455
Email Addresses:
[email protected]
Total Funding:
135.69 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving WordPress Google Maps SSL By Default HSTS IPv6 Cloudflare Hosting Sitelinks Search Box
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Forty Seven
Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Series C - Amphivena Therapeutics
+ND Capital
+ND Capital investment in Series C - Amphivena Therapeutics
Industrial Investors Group
Industrial Investors Group investment in Series C - Amphivena Therapeutics
Solasta Ventures
Solasta Ventures investment in Series C - Amphivena Therapeutics
Clough Capital Partners
Clough Capital Partners investment in Series C - Amphivena Therapeutics
Franklin Berger
Franklin Berger investment in Series C - Amphivena Therapeutics
Newton Investment Management
Newton Investment Management investment in Series C - Amphivena Therapeutics
Mérieux Equity Partners
Mérieux Equity Partners investment in Series C - Amphivena Therapeutics
Aju IB Investment
Aju IB Investment investment in Series C - Amphivena Therapeutics
MPM Capital
MPM Capital investment in Series C - Amphivena Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-02 | Amphivena Therapeutics appoints president and CEO |
Official Site Inspections
http://www.amphivena.com
- Host name: 172.67.219.95
- IP address: 172.67.219.95
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amphivena Therapeutics"
Amphivena Therapeutics - Crunchbase Company …
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T …See details»
Amphivena Therapeutics Inc - LinkedIn
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics …See details»
Amphivena Therapeutics Company Profile 2024: Valuation, …
Nov 21, 2017 Amphivena Therapeutics was founded in 2012. Where is Amphivena Therapeutics headquartered? Amphivena Therapeutics is headquartered in South San Francisco, CA. What …See details»
Amphivena Therapeutics - Funding, Financials, Valuation & Investors
Amphivena Therapeutics is funded by 14 investors. Qiming Venture Partners and +ND Capital are the most recent investors. Amphivena Therapeutics has a post-money valuation in the range …See details»
Amphivena Therapeutics, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Amphivena Therapeutics, Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
Amphivena Therapeutics - Contacts, Employees, Board Members, …
Organization. Amphivena Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. Amphivena Therapeutics has 3 current employee …See details»
AMPHIVENA THERAPEUTICS INC Company Profile - Dun
Amphivena therapeutics inc. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united states …See details»
Amphivena Presents New Monotherapy and First Combination …
Jun 4, 2021 Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla …See details»
Amphivena Therapeutics - VentureRadar
Amphivena Therapeutics, in collaboration with Affimed AG, is developing bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats (~100kD) that …See details»
Amphivena Therapeutics Inc. - VentureRadar
Amphivena Therapeutics Inc. is a drug discovery company developing bispecific TandAb antibodies to treat hematological tumors. The company is a subsidiary of Affimed Therapeutics …See details»
Amphivena Therapeutics - Craft
Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting. Apr 12, 2021. Amphivena …See details»
Mission, Vision & Core Values of Amphivena Therapeutics
Dec 19, 2024 As a clinical-stage immuno-oncology company, Amphivena Therapeutics is dedicated to making a lasting impact on the field of oncology through its mission, vision, and …See details»
Amphivena Therapeutics: Advancing Cancer Immunotherapy
Amphivena Therapeutics, Inc. is one such clinical-stage, immuno-oncology company with a novel platform of T cell engagers (Amphivena ReSTOREâ„¢) that directly targets myeloid derived …See details»
Amphivena Closes $62 Million Series C Financing to Expand
Sep 24, 2019 Amphivena Therapeutics, Inc. is an immuno-oncology company based in South San Francisco, CA that is developing best-in-class T cell engagers for cancer. The company’s …See details»
Quiet biotech Amphivena nabs $62M funding round
Sep 24, 2019 Little-known and super quiet biotech Amphivena Therapeutics has grabbed a strong and healthy $62 million series C round funding haul.. The Californian company, which …See details»
Amphivena Therapeutics - Updates, News, Events, Signals & Triggers
Amphivena Therapeutics is focused on developing biologics for immuno-oncology, specifically targeting acute myeloid leukemia (AML) and solid tumors. Their research includes methods …See details»
Amphivena closes $62m Series C financing to expand clinical …
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C …See details»
Amphivena Presents Translational Data Highlighting the Cytokine …
Apr 12, 2021 Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action …See details»
Amphivena Therapeutics Presents Positive Data on Novel Acute …
Jun 1, 2015 Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced positive data from several preclinical studies characterizing the company's …See details»
Amphivena Therapeutics Announces First Patient Dosed in the …
Dec 16, 2020 Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla …See details»